Laurence Klotz, MD, presented “The miR Scientific Sentinel Assay” during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in October 2020.
How to cite: Klotz, Laurence. “The miR Scientific Sentinel Assay” October 2020. Accessed Dec 2024. https://grandroundsinurology.com/the-mir-scientific-sentinel-assay/
The miR Scientific Sentinel Assay – Summary
Laurence Klotz, MD, Professor of Surgery and holder of the Sunnybrook Chair of Prostate Cancer Research at the University of Toronto, explains how the miR Scientific Sentinel Assay works and its potential benefits for patients with prostate cancer. Dr. Klotz uses results from a September 2020 study to display how the Sentinel PCa, CS, and HG Tests demonstrate high levels of sensitivity and specificity in these patients. The Sentinel™ PCa Test classifies patients based on absence or presence of disease, the miR Sentinel CS Test stratifies patients based on low-risk disease (Grade Group 1) or intermediate- and high-risk disease (Grade Groups 2-5), and the miR Sentinel HG Test stratifies patients based on low- and favorable intermediate-risk disease (Grade Groups 1 or 2) or high-risk disease (Grade Groups 3-5). This is the first report of the development and performance of a platform that interrogates small noncoding RNAs (sncRNA) isolated from urinary exosomes, and highlights the utility of these non-invasive, highly precise techniques for diagnosing and classifying prostate cancer.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Laurence Klotz, MD, FRCSC, is a professor of surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research. Dr. Klotz was the founding editor-in-chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal (CUAJ), and he is now editor emeritus of the CUAJ. Dr. Klotz obtained his medical degree and completed his residency at the University of Toronto. He was also a uro-oncology fellow at Memorial Sloan Kettering Cancer Center in New York.
Dr. Klotz has 550 peer review publications and eight books. He coined the phrase “active surveillance” and successfully championed this approach for men with favorable-risk prostate cancer against substantial resistance. He was the associate editor of the Journal of Urology, responsible for prostate cancer, for eight years. Dr. Klotz received the Queen’s Jubilee Medal for outstanding public service, the University of Toronto's Lister Prize, the Society of Urologic Oncology’s SUO Medal, the American Urological Association’s Richard Williams Award, the University of Toronto's Lifetime Achievement Award, the Canadian Urological Association Lifetime Achievement Award, and the Harold Warwick Award from the Canadian Cancer Society for “outstanding contributions to cancer control.” In 2015 he was inducted as a Member of the Order of Canada, Canada’s highest civilian award.